Form 4: Shuttle Pharma Director Granted RSUs

Shuttle Pharmaceuticals Holdings, Inc. Director Joseph Tung was granted 29,240 Restricted Stock Units, vesting over three years.

Summary

• Joseph Tung, a Director of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted 29,240 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of common stock.
• The RSUs were granted on August 8, 2025, with a vesting schedule of one-third on August 8, 2026, August 8, 2027, and August 8, 2028.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a routine compensation event, aligning management's interests with shareholders over the long term, which is generally viewed as a positive for corporate governance and stability.

Positives

• The grant of Restricted Stock Units to a director aligns their long-term interests with those of the shareholders.
• The multi-year vesting schedule encourages retention and continued commitment from key personnel.

Negatives

• The grant of RSUs does not provide immediate cash compensation to the director.
• Future conversion of RSUs into common stock will result in minor dilution for existing shareholders.

Risks

• Potential future dilution of existing shareholders upon the vesting and conversion of the Restricted Stock Units into common stock.

Future Outlook

The future outlook involves the vesting of the granted Restricted Stock Units over the next three years, leading to the potential issuance of 29,240 shares of common stock to the director.

Industry Context

The grant of Restricted Stock Units is a common form of equity compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize directors and executives by aligning their financial interests with long-term company performance.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units, are a standard component of director compensation packages across the biotech and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use such instruments to incentivize leadership.
• The vesting schedule over multiple years is typical for long-term incentive plans, ensuring sustained commitment from the director.

Related Party Transactions

• The grant of Restricted Stock Units to Joseph Tung, a Director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the future vesting and conversion of RSUs into common stock, but improved alignment of director's interests with shareholder value.
• Employees: No direct impact on general employees from this specific director grant.

Next Steps

• Vesting of 9,747 RSUs on August 8, 2026.
• Vesting of 9,747 RSUs on August 8, 2027.
• Vesting of 9,746 RSUs on August 8, 2028.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new fundamental information to alter an investment thesis. It aligns the director's interests with shareholders but does not indicate significant operational or financial changes that would warrant a change in investment recommendation.

Keywords

Shuttle Pharmaceuticals, SHPH, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Joseph Tung, Insider Transaction